From the Guidelines
Humira (adalimumab) typically does not cause increased white blood cell (WBC) count or C-reactive protein (CRP) levels, as it is designed to reduce inflammation in the body, leading to decreases in inflammatory markers like CRP. In fact, as a TNF-alpha inhibitor, Humira works by blocking the action of tumor necrosis factor-alpha, a substance in the body that causes inflammation and is involved in autoimmune diseases such as rheumatoid arthritis 1. During treatment with Humira, many patients experience normalization of previously elevated inflammatory markers as their underlying inflammatory condition improves. However, if a patient on Humira develops an infection (which is a potential side effect due to the medication's immunosuppressive properties), this could secondarily cause elevated WBC and CRP levels. Regular blood monitoring is recommended for patients on Humira to track these parameters, including WBC and CRP levels, as well as to monitor for potential side effects such as infection or bone marrow suppression 1. If a patient on Humira notices unexplained increases in WBC or CRP, they should contact their healthcare provider promptly as this could indicate an infection or other complication requiring medical attention. Some key points to consider when monitoring patients on Humira include:
- Regular blood tests to monitor WBC and CRP levels
- Monitoring for signs of infection, such as fever or chills
- Monitoring for potential side effects, such as bone marrow suppression or liver damage
- Adjusting the dose or discontinuing treatment if necessary to minimize the risk of adverse effects. It's also important to note that Humira can increase the risk of serious infections, and patients should be advised to seek medical attention immediately if they experience any signs of infection, such as fever, chills, or cough 1. Overall, while Humira is generally well-tolerated, regular monitoring and prompt medical attention are essential to minimize the risk of adverse effects and ensure the best possible outcomes for patients.
From the Research
Humira (Adalimumab) and White Blood Cell (WBC) Count or C-Reactive Protein (CRP) Levels
- There are no research papers provided that directly investigate the effect of Humira (adalimumab) on White Blood Cell (WBC) count or C-Reactive Protein (CRP) levels.
- However, studies on glucocorticoids and corticosteroids provide some insight into the potential effects of immunosuppressive drugs on WBC count and CRP levels 2, 3, 4, 5.
- Glucocorticoids have been shown to increase WBC count, particularly neutrophil count, while decreasing CRP levels 2, 3, 4, 5.
- The exact mechanism of Humira (adalimumab) on WBC count and CRP levels is not addressed in the provided studies, and more research would be needed to determine its specific effects.
- In the absence of direct evidence, it is unclear whether Humira (adalimumab) would have a similar effect on WBC count and CRP levels as glucocorticoids and corticosteroids 6.